Homocysteine levels and early heart function changes in new high blood pressure
Examines whether high homocysteine relates to early heart problems in adults newly diagnosed with hypertension.
Plain-language title generated from the registry record
Registry title: Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension
Key facts
- Where
- Konya, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose high blood pressure (essential hypertension) was found within the last 6 months. It will compare heart function in people with high and normal homocysteine levels.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed essential hypertension, within the previous 6 months.
- Earlier treatment
- People currently taking or being treated with folate, vitamin B12 or vitamin B6 cannot join.
Main reasons for not taking part
- Resistant or secondary hypertension
- Known heart failure, pulmonary hypertension or congenital heart disease
- Atrial fibrillation or atrial flutter
- Chronic kidney disease or anemia
- Acute coronary syndrome or major surgery within the previous 6 months
Read by machine on 13 November 2026.
Where in Türkiye
- Necmettin Erbakan University Meram Faculty of MedicineKonya, TürkiyeContact: YUNUS EMRE YAVUZ, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Necmettin Erbakan University
- Trial code
- NCT07480265
- Record updated
- 24 March 2026
- Original description
This prospective single-center observational study aims to evaluate the relationship between elevated plasma homocysteine levels and early echocardiographic abnormalities in patients with newly diagnosed essential hypertension. Adult patients diagnosed with essential hypertension within the previous 6 months will undergo clinical assessment, ambulatory blood pressure monitoring, electrocardiography, laboratory testing, and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis when image quality is adequate. Participants will be classified according to plasma homocysteine level using, and patients with elevated and normal homocysteine levels will be compared with respect to diastolic dysfunction and left ventricular and left atrial global longitudinal strain parameters. Clinical, laboratory, and echocardiographic data will also be used to develop a machine-learning based model for prediction of H-type hypertension.Read full original descriptionShow less
Relationship Between Elevated Homocysteine Levels and Early Diastolic Dysfunction in Newly Diagnosed Hypertensive Patients
This prospective single-center observational study aims to evaluate the relationship between elevated plasma homocysteine levels and early echocardiographic abnormalities in patients with newly diagnosed essential hypertension. Adult patients diagnosed with essential hypertension within the previous 6 months will undergo clinical assessment, ambulatory blood pressure monitoring, electrocardiography, laboratory testing, and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis when image quality is adequate. Participants will be classified according to plasma homocysteine level using, and patients with elevated and normal homocysteine levels will be compared with respect to diastolic dysfunction and left ventricular and left atrial global longitudinal strain parameters. Clinical, laboratory, and echocardiographic data will also be used to develop a machine-learning based model for prediction of H-type hypertension.
Inclusion: Adults aged 18 years or older; Newly diagnosed essential hypertension within the previous 6 months; Ability and willingness to provide informed consent; Availability for clinical evaluation, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and transthoracic echocardiography.
Exclusion: Acute coronary syndrome within the previous 6 months; Major surgery within the previous 6 months; Resistant hypertension; Secondary hypertension; Known heart failure; Pulmonary hypertension; Congenital heart disease; Moderate or severe valvular heart disease; Chronic kidney disease; Known systemic conditions that may significantly affect plasma homocysteine levels; Atrial fibrillation or atrial flutter; Anemia; Current folate, vitamin B12, or vitamin B6 supplementation or treatment; Inadequate echocardiographic image quality for strain analysis.